Anderson Financial Strategies LLC Buys 78,488 Shares of Bioventus Inc. $BVS

Anderson Financial Strategies LLC boosted its stake in Bioventus Inc. (NASDAQ:BVS) by 58.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 213,208 shares of the company’s stock after buying an additional 78,488 shares during the quarter. Bioventus comprises 0.9% of Anderson Financial Strategies LLC’s holdings, making the stock its 26th largest holding. Anderson Financial Strategies LLC’s holdings in Bioventus were worth $1,586,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BVS. Prelude Capital Management LLC bought a new position in shares of Bioventus in the 3rd quarter worth about $74,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Bioventus during the third quarter valued at approximately $78,000. SG Americas Securities LLC purchased a new position in shares of Bioventus during the fourth quarter valued at approximately $80,000. Brooklyn Investment Group purchased a new position in shares of Bioventus during the fourth quarter valued at approximately $91,000. Finally, Truist Financial Corp bought a new stake in shares of Bioventus in the 4th quarter worth approximately $93,000. 62.94% of the stock is owned by institutional investors.

Bioventus Stock Up 2.0%

Bioventus stock opened at $8.71 on Friday. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $11.25. The stock has a fifty day simple moving average of $9.57 and a two-hundred day simple moving average of $8.67. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. The firm has a market cap of $727.63 million, a price-to-earnings ratio of 21.24, a PEG ratio of 1.10 and a beta of 0.67.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The firm had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities analysts predict that Bioventus Inc. will post 0.77 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research note on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. Craig Hallum increased their target price on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Finally, CJS Securities initiated coverage on Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $14.20.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.